Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Apatinib mesylate by Elevar Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According...
Apatinib mesylate by Elevar Therapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According...
Apatinib mesylate by Elevar Therapeutics for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...
Apatinib mesylate by Elevar Therapeutics for Metastatic Pancreatic Cancer: Likelihood of Approval
Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase II for Metastatic Pancreatic Cancer. According to...
Apatinib mesylate by Elevar Therapeutics for Synovial Sarcoma: Likelihood of Approval
Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase I for Synovial Sarcoma. According to GlobalData,...
Apatinib mesylate by Elevar Therapeutics for Melanoma: Likelihood of Approval
Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase I for Melanoma. According to GlobalData, Phase...
Apatinib mesylate by Elevar Therapeutics for Leiomyosarcoma: Likelihood of Approval
Apatinib mesylate is under clinical development by Elevar Therapeutics and currently in Phase I for Leiomyosarcoma. According to GlobalData, Phase...